Industry Hotspot | General Manager Wang Xiaoya Awarded “2022 Leader in China’s In Vitro Diagnostic Industry”

Posted by

6 2 月, 2026

On 6 2 月, 2026

Introduction:

The 10th China In Vitro Diagnostic Industry Development Conference, hosted by the Medical Laboratory Industry Branch of the National Health Industry Enterprise Management Association and co-organized by the Experimental Medicine Branch of the National Health Industry Enterprise Management Association, was grandly held at the GreenTree Premier Hotel Conference Center in Nanchang International Expo City from May 28 to 29, 2023.

During the conference, the award list for “2022 China In Vitro Diagnostic Industry Leading Figures” was announced.Mr. Wang Xiaoya, General Manager of Maxin Biotech, received this honor and was recognized!

Industry Leading Figures Award Ceremony

Through a rigorous evaluation process, a total of 9 meritorious entrepreneurs from China’s in vitro diagnostic industry were successfully selected for the 2022 China In Vitro Diagnostic Industry Leading Figures selection activity.

It is worth mentioning thatMr. Wang’s selection as a “2022 China In Vitro Diagnostic Industry Leading Figure” marks the first time a representative from a domestic enterprise in the pathology subfield of in vitro diagnostics has been selected.this not only represents the industry’s full recognition of Maxin Biotech’sIn the pathology track,contributions over the past thirty years in continuously breaking foreign technological monopolies and promoting the localization of pathology products,it also signifies that in the era of precision medicine, the importance of pathological diagnosis is receiving more attention and emphasis, and it will occupy a more significant position in the future in vitro diagnostic industry..

Focusing on Industry Trends, Co-creating the Future Blueprint

On the afternoon of the 29th, a large-scale interview with entrepreneurs from the in vitro diagnostic industry was the grand finale of the conference. Numerous experts from pathology, laboratory testing, and clinical frontline shared their views and engaged in discussions and exchanges on topics such as technological innovation and R&D in the in vitro diagnostic industry, overseas market expansion, and industry centralized procurement.

During the interview, the host asked about the secret to Maxin Biotech’s leading position in the pathology track. Mr. Wang, from the perspective of the pathology diagnostic submarket, shared his insights on issues related to the in vitro diagnostic industry with the attendees. He stated that in the fierce market competition, technological innovation and talent cultivation are key to supporting a company’s success. At the same time,in the post-pandemic era, with the development and application of new technologies, the in vitro diagnostic industry will experience rapid development, and pathological diagnosis will also play an important role, with promising prospects for the future.

Award Acceptance Speech

In a post-conference interview, Mr. Wang expressed that this award is not only a personal honor but also recognition and encouragement for Maxin Biotech’s relentless efforts over the past thirty years. It also indicates that pathological diagnosis is increasingly receiving more attention and emphasis in the medical field. Taking this opportunity, Mr. Wang thanked the co-founding team of Maxin Biotech, senior pathology experts, and colleagues who have consistently supported and trusted Maxin. In the future, Maxin Biotech will continue to be committed to promoting the development of the industry, advancing on the path of precision medicine, and living up to expectations with initial passion and the highest quality standards, striving to reach new heights.

发表回复 取消回复

发表回复取消回复